Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Invested Capital (2016 - 2025)

Historic Invested Capital for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $52.9 million.

  • Protalix BioTherapeutics' Invested Capital rose 6311.0% to $52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.9 million, marking a year-over-year increase of 6311.0%. This contributed to the annual value of $43.2 million for FY2024, which is 1971.2% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Invested Capital of $52.9 million as of Q3 2025, which was up 6311.0% from $49.9 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Invested Capital ranged from a high of $69.9 million in Q1 2021 and a low of -$11.5 million during Q3 2022
  • Over the past 5 years, Protalix BioTherapeutics' median Invested Capital value was $43.2 million (recorded in 2024), while the average stood at $29.6 million.
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 43354.58% in 2022, then surged by 488075.4% in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Invested Capital stood at -$6.0 million in 2021, then tumbled by 76.28% to -$10.6 million in 2022, then skyrocketed by 605.83% to $53.8 million in 2023, then decreased by 19.71% to $43.2 million in 2024, then rose by 22.44% to $52.9 million in 2025.
  • Its Invested Capital was $52.9 million in Q3 2025, compared to $49.9 million in Q2 2025 and $45.2 million in Q1 2025.